Ritlecitinib (Litfulo): the alopecia areata treatment that changes the game

For a condition that had almost no effective options, that is a real turning point. Alopecia areata affects roughly 2% of the population over a lifetime. It strikes without warning. Round patches. Sometimes the whole scalp. Sometimes every hair on the body. Here we explain what ritlecitinib actually is, how it works, what the clinical trials show, and who it is for. No hype. With the real numbers.

Alopecia areata is not ordinary baldness

The first thing to understand, and it matters a great deal. Alopecia areata has nothing to do with ordinary hereditary hair loss.

Androgenetic alopecia, the kind that thins the temples and the crown, is driven by a hormone, DHT, which slowly shrinks the follicles. It is mechanical, hormonal, slow. Alopecia areata is an autoimmune disease. Your own immune system attacks your hair follicles as if they were intruders.

Picture bodyguards who have turned paranoid. They are meant to protect the body, yet they turn on healthy follicles and force them into a state of rest. The hair falls out in patches, often within a few weeks. The good news inside the bad: the follicle is not destroyed. It is asleep, not dead. That is exactly what makes regrowth possible.

This distinction changes everything on the treatment side. Blocking DHT has no effect on alopecia areata. Here, you have to calm the immune system. And this is where JAK inhibitors come in.

When the immune system attacks the hair

In alopecia areata, immune cells called T lymphocytes cluster around the hair bulb. They release inflammatory signals, in particular interferon gamma and a molecule called interleukin 15. These signals travel along a communication route inside the cell: the JAK-STAT pathway.

Think of a messaging system. The inflammatory signal knocks at the cell door, and the JAK enzymes pass the message inside. The result: the attack intensifies, the follicle stops growing. Cut that messaging, and you cut the order to attack.

Alopecia areata can take wider forms. Alopecia universalis causes loss of every hair on the body. Alopecia barbae targets the beard. All share the same underlying autoimmune mechanism.

Ritlecitinib: how it works exactly

Ritlecitinib is a kinase inhibitor. In plain terms, it blocks the enzymes that pass on the attack signals. But it has a feature that sets it apart from other treatments in its family.

It hits two targets at once. First JAK3, an enzyme in the JAK-STAT pathway. Then the TEC family, another group of enzymes involved in activating T lymphocytes. By locking these two doors, ritlecitinib reduces the production of inflammatory cytokines and directly calms the immune cells attacking the follicle.

In other words, it works on two fronts of the same conflict. It intercepts the inflammatory message and it disarms some of the soldiers. Once the attack lifts, the sleeping follicles can resume their normal growth cycle.

The treatment is taken orally, one capsule a day. The approved dose is 50 mg. No injection, no topical application. And unlike the corticosteroids used against alopecia areata for decades, this is not a blunt, body-wide immune hit but a more targeted block.

A more selective target

That selectivity counts. The first JAK inhibitors tested against alopecia areata blocked a wide range of enzymes, with effects across the whole body. Ritlecitinib instead focuses on JAK3 and TEC, players that are abundant in immune cells but quiet elsewhere. The idea: aim precisely, limit the collateral damage.

What the ALLEGRO trials show

The numbers come from the ALLEGRO programme, a large clinical trial run by Pfizer. The phase 2b/3 study recruited 718 patients aged 12 and over, across 18 countries. All had severe alopecia areata, with at least 50% of the scalp bare.

The main measure rested on a tool called the SALT score. It measures the percentage of scalp without hair, from 0 (a full head of hair) to 100 (total baldness). The target set: reach a SALT score of 20 or below, meaning at most 20% of the scalp still bare. In plain terms, regrowing 80% of your hair.

The results at six months

By week 24, 23% of patients on ritlecitinib 50 mg crossed that threshold. In the placebo group: barely 2%. A clear gap, enough to validate the drug.

But regrowth does not stop there. It continues over time. By week 48, a year in, the share of responders climbed to 43%. Patience pays: the reawakened follicles take months to rebuild a dense head of hair.

And in adolescents

This is one of the major contributions of ritlecitinib. Before it, no treatment was approved for young people. Yet alopecia areata often strikes early, at an age when other people’s looks weigh heavily. In the adolescent subgroup of the trial, between 17% and 28% of young people on effective doses reached a SALT score of 20 or below by week 24. Against 0% on placebo.

The eyelashes and eyebrows too

Alopecia areata does not affect only the scalp. Losing your eyebrows and eyelashes changes a face, and it is often felt as very hard. The trials tracked this specific regrowth with dedicated scales. And the results are there. By week 48, around 71% of patients on 50 mg had regrown normal or markedly improved eyebrows. For the eyelashes, regrowth followed the same trend. For many, this is the detail that brings back a familiar face in the mirror.

Over the longer term, the follow-up data from the ALLEGRO-LT study point the same way. At two years, close to 73% of patients reached a SALT score of 20 or below, and about 66% a score of 10 or below, meaning nearly all the hair recovered.

Side effects: what you need to know

No drug comes without a trade-off, and pretending otherwise would be dishonest. Let us be clear about the numbers.

In the safety analysis pooling patients across the trials, the overall rate of adverse events on ritlecitinib was comparable to placebo. The most common ones stay mild: headache, nasopharyngitis (the common cold), acne, diarrhoea. Nothing dramatic for most patients.

Serious events stayed rare. A few cases of shingles were seen, a known effect of this family of drugs, which acts on the immune system. That is precisely why medical monitoring is essential.

Monitoring, part of the treatment

Before starting, a blood test is needed. During treatment, the doctor watches certain values: white blood cells, platelets, sometimes liver function. This is not a formality. It is what allows any adverse reaction to be caught early.

Like all JAK inhibitors, ritlecitinib carries a safety warning about possible risks of serious infections, blood clots and certain cancers, seen mainly in other conditions. Hence the importance of prescription by a specialist, who weighs the benefit against the risk for each profile.

Who is this treatment for

Ritlecitinib is for people aged 12 and over with severe alopecia areata. Not the small isolated patch that often regrows on its own. We are talking here about widespread, resistant forms that genuinely weigh on daily life.

An honest point, and it counts. The treatment is not a permanent cure. Alopecia areata is a chronic disease. When the drug is stopped, regrowth can reverse and the hair can fall out again, because the underlying autoimmune cause is still there. Ritlecitinib controls the disease, it does not erase it.

It does not suit everyone either. A history of serious infections, certain cancers, a fragile immune state: all situations that call for caution. And it takes patience. The first signs of regrowth often appear around the third or fourth month, sometimes later. Watching a sleeping follicle wake up takes time.

Finally, let us state the obvious. This drug only concerns autoimmune alopecia areata. It is of no use against androgenetic alopecia, nor against telogen effluvium linked to stress, nor against traction alopecia. The right treatment always depends on the right diagnosis.

Why a hair transplant is not the answer for alopecia areata

Here is the point many patients misunderstand, and it needs saying clearly. Alopecia areata is not treated with a hair transplant. Never. And for a reason that is easy to grasp.

A transplant moves follicles from one area to another. That makes sense when the problem is local. But in alopecia areata, the problem is not local: it is your immune system that attacks. And it does not tell the difference between a native follicle and a transplanted one. Putting hair into a scalp in the middle of active alopecia areata would mean handing those grafts to the same autoimmune attack. They would fall out like the rest. It is a waste of effort.

Add to that something few people know: alopecia areata can regrow on its own. Spontaneously. An isolated patch often closes up with no treatment at all. Operating on a scalp that might have recovered by itself makes no sense. The right answer to alopecia areata is medical, not surgical. That is exactly the role of treatments like ritlecitinib: calm the disease so the sleeping follicles can wake up.

Dr Cinik’s role: first, get the diagnosis right

So what use is a hair transplant surgeon faced with alopecia areata? To not operate. And that is precisely where the value lies.

The first useful step is not surgery. It is the diagnosis. A patch on the scalp can hide a great deal: alopecia areata, a localised hair loss, a scarring alopecia, early androgenetic alopecia, or something else again. Each calls for a different response. Confusing alopecia areata (autoimmune, to be treated medically) with androgenetic alopecia (mechanical, sometimes eligible for a transplant) leads straight to the wrong decision.

Dr Emrah Cinik plays a role of honest guidance here. Telling apart what calls for medical treatment from what calls for surgery. If it is alopecia areata, you do not transplant: you point the patient towards the right treatment, such as ritlecitinib, and you give the disease time to settle.

A hair transplant keeps all its sense, but for other situations: a non-autoimmune alopecia, or an old, stabilised alopecia areata that has left permanently bare areas once the disease burned out. In those cases, Dr Cinik’s advanced techniques such as the Sapphire FUE and DHI give natural, lasting results. Treatments such as PRP or hair mesotherapy can support density.

With over 20 years of experience, more than 50,000 patients and protocols in line with the international ISHRS standards, Dr Cinik’s team assesses each case individually. If you notice patches appearing and you do not know what they are, start there: ask for a free, no-obligation diagnosis. It pinpoints your type of alopecia and points you towards the solution that genuinely fits, whether medical or surgical. Sometimes the best advice a surgeon can give is to tell you that you do not need him.

Scientific references

King, B., Zhang, X., Harcha, W. G., Szepietowski, J. C., Shapiro, J., Lynde, C., Mesinkovska, N. A., Zwillich, S. H., Napatalung, L., Wajsbrot, D., Fayyad, R., Freyman, A., Mitra, D., Purohit, V., Sinclair, R., & Wolk, R. (2023). Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. The Lancet, 401(10387), 1518-1529. https://pubmed.ncbi.nlm.nih.gov/36773619/

King, B., Mesinkovska, N. A., Craiglow, B., Kindred, C., Ko, J., McCollam, J., Bhatia, N., Lim, H. W., Napatalung, L., Wajsbrot, D., Fayyad, R., Freyman, A., & Tran, H. (2023). Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology. https://pubmed.ncbi.nlm.nih.gov/37455588/

King, B., Soung, J., Tziotzios, C., Rudnicka, L., Joly, P., Gooderham, M., Sinclair, R., Mesinkovska, N. A., Craiglow, B., Tran, H., Tatla, D., Wajsbrot, D., Wolk, R., & Sun, X. (2024). Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. American Journal of Clinical Dermatology, 25(2), 299-314. https://pmc.ncbi.nlm.nih.gov/articles/PMC10867086/

U.S. Food and Drug Administration. (2023). Drug Trials Snapshots: LITFULO (ritlecitinib). https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-litfulo

Pfizer. (2023). FDA Approves Pfizer’s LITFULO (ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata. https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-litfulotm-ritlecitinib-adults-and

National Alopecia Areata Foundation. (2023). LITFULO (ritlecitinib) FAQ. https://www.naaf.org/litfulo-ritlecitinib-faq-2/